The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
Open accessAbstract
BACKGROUND: Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme are associated with an increased risk of coronary events. Darapladib is a selective oral inhibitor of lipoprotein-associated phospholipase A2. METHODS: In a double-blind trial, we randomly assigned 15,828 patients with stable coronary heart disease to receive either once-daily darapladib (at a dose of 160 mg) or placebo. The primary end point was a composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included the components of the primary end point as well as major coronary events (death from coronary heart disease, myocardial infarction, or urgent coronary revascularization for myocardial ischemia) and total coronary events (death from coronary heart disease, myocardial infarction, hospitalization for unstable angina, or any coronary revascularization). RESULTS: During a median follow-up period of 3.7 years, the primary end point occurred in 769 of 7924 patients (9.7%) in the darapladib group and 819 of 7904 patients (10.4%) in the placebo group (hazard ratio in the darapladib group, 0.94; 95% confidence interval [CI], 0.85 to 1.03; P=0.20). There were also no significant between-group differences in the rates of the individual components of the primary end point or in all-cause mortality. Darapladib, as compared with placebo, reduced the rate of major coronary events (9.3% vs. 10.3%; hazard ratio, 0.90; 95% CI, 0.82 to 1.00; P=0.045) and total coronary events (14.6% vs. 16.1%; hazard ratio, 0.91; 95% CI, 0.84 to 0.98; P=0.02). CONCLUSIONS: In patients with stable coronary heart disease, darapladib did not significantly reduce the risk of the primary composite end point of cardiovascular death, myocardial infarction, or stroke. (Funded by GlaxoSmithKline; STABILITY ClinicalTrials.gov number, NCT00799903.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, no change in Lp-PLA2 over time was observed in the placebo arms of trials evaluating potential inhibitors of this pathway 18,19 or in studies of stability of circulating Lp-PLA2 levels over time.20”
From Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy (2022) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bhatt, D. L. (2006) · JAMA · doi:10.1001/jama.295.2.180 · Cited by 1,644
Concept of Vulnerable/Unstable Plaque
Finn, A. V., Nakano, M., Narula, J., Kolodgie, F. D., & Virmani, R. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179739 · Cited by 1,193
Bhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Steg, P. G., Greenlaw, N., Tardif, J., Tendera, M., Ford, I., Kääb, S., Abergel, H., Fox, K. M., Ferrari, R., & on behalf of the CLARIFY Registry Investigators (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs289 · Cited by 653
Serruys, P. W. J. C., García‐García, H. M., Buszman, P. E., Erné, P., Verheye, S., Aschermann, M., Duckers, H., Bleie, Ø., Dudek, D., Bøtker, H. E., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.771899 · Cited by 498
Wilensky, R. L., Shi, Y., Mohler, E. R., Hamamdzic, D., Burgert, M. E., Li, J., Postle, A. D., Fenning, R. S., Bollinger, J. G., Hoffman, B. E., et al. (2008) · Nature Medicine · doi:10.1038/nm.1870 · Cited by 389
Macphee, C. H., Moores, K., Boyd, H., Dhanak, D., Ife, R. J., Leach, C. A., Leake, D. S., Milliner, K. J., Patterson, R. A., Suckling, K. E., et al. (1999) · Biochemical Journal · doi:10.1042/bj3380479 · Cited by 359
Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular Disease
Brosius, F. C., Hostetter, T. H., Kelepouris, E., Mitsnefes, M. M., Moe, S. M., Moore, M. A., Pennathur, S., Smith, G. L., & Wilson, P. W. F. (2006) · Circulation · doi:10.1161/circulationaha.106.177321 · Cited by 325
Kolodgie, F. D., BURKE, A. P., Skorija, K., Ladich, E. R., Kutys, R., Makuria, A. T., & Virmani, R. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000244681.72738.bc · Cited by 307
Research works printed but not linked: 1
- 10.1042/0264-6021:3380479 · DOI
Cited by
Sorted by citations
Items 201–300 of 588
Metabolic and Molecular Imaging of Atherosclerosis and Venous Thromboembolism
Osborn, E. A., Kessinger, C. W., Tawakol, A. A., & Jaffer, F. A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.182873 · Cited by 31
Santoso, A., Heriansyah, T., & Rohman, M. S. (2019) · Current Cardiology Reviews · doi:10.2174/1573403x15666190531111932 · Cited by 31
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 41
Cai, A., Li, G., Chen, J., Li, X., Li, L., & Zhou, Y. (2015) · BMC Cardiovascular Disorders · doi:10.1186/s12872-015-0001-9 · Cited by 30
Hassan, M. S. (2015) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2015.6 · Cited by 29
Therapeutic Approaches Targeting Inflammation in Cardiovascular Disorders
Jones, D., & Patel, J. (2018) · Biology · doi:10.3390/biology7040049 · Cited by 30
Zhang, H., Gao, Y., Wu, D., & Zhang, D. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01580-4 · Cited by 29
Singh, D., Rai, V., & Agrawal, D. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213731 · Cited by 29
Li, Z., Lin, C., Cai, X., Hu, S., Lv, F., Yang, W., Zhu, X., & Ji, L. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.06.972 · Cited by 30
The vulnerable atherosclerotic plaque: in vivo identification and potential therapeutic avenues
Adamson, P. D., Dweck, M. R., & Newby, D. E. (2015) · Heart · doi:10.1136/heartjnl-2014-307099 · Cited by 30
y, P. A., Bayés‐Genís, A., de Isla, L. P., Sanchis, J., & Heras, M. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.04.004 · Cited by 28
Serum Neurofilament Light Chain in Patients With Atrial Fibrillation
Sjölin, K., Aulin, J., Wallentin, L. C., Eriksson, N., Held, C., Kultima, K., Oldgren, J., & Burman, J. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025910 · Cited by 28
Millwood, I. Y., Bennett, D., Walters, R. G., Clarke, R., Waterworth, D. M., Johnson, T., Chen, Y., Yang, L., Yu, C., Bian, Z., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.056 · Cited by 27
Anti-inflammatory Therapies for Coronary Heart Disease: A Systematic Review and Meta-Analysis
Wang, H., Jiang, M., Li, X., Zhao, Y., Shao, J., Liu, Z., Lin, L., Xu, Q., Wang, L., Lu, X.-C., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.726341 · Cited by 27
Niu, Y., Bai, N., Ma, Y., Zhong, P.-Y., Shang, Y.-S., & Wang, Z.-L. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02525-9 · Cited by 26
Vyletelová, V., Nováková, M., & Pašková, Ľ. (2022) · Pharmaceuticals · doi:10.3390/ph15101278 · Cited by 30
Fanaroff, A. C., Clare, R. M., Pieper, K. S., Mahaffey, K. W., Melloni, C., Green, J. B., Alexander, J. H., Jones, W. S., Harrison, R. W., Mehta, R. H., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037202 · Cited by 26
Short-term changes in arterial inflammation predict long-term changes in atherosclerosis progression
Joseph, P. G., Ishai, A., Mani, V., Kallend, D. G., Rudd, J. H. F., Fayad, Z. A., & Tawakol, A. A. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3524-0 · Cited by 26
Inflammation Revisited: Atherosclerosis in The Post-CANTOS Era
Köenig, W., & Deutsches Herzzentrum München, T. U. M. (2017) · European Cardiology Review · doi:10.15420/ecr.2017:18:1 · Cited by 26
Baziar, N., Nasli‐Esfahani, E., Djafarian, K., Qorbani, M., Hedayati, M., Mishani, M. A., Faghfoori, Z., Ahmaripour, N., & Hosseini, S. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5850865 · Cited by 28
Korsnes, J. S., Davis, K. L., Ariely, R., Bell, C. F., & Mitra, D. (2015) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2015.21.6.443 · Cited by 26
Advances in non-invasive drug delivery for atherosclerotic heart disease
Maranhão, R. C., & Tavares, E. R. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.999663 · Cited by 25
Yeo, A. J. M., Li, L., Warren, L. L., Aponte, J. L., Fraser, D. J., King, K. S., Johansson, K. A., Barnes, A., Macphee, C. H., Davies, R., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182115 · Cited by 24
Huang, Y., Wu, Y., Yang, Y., Li, W., Lu, J., & Hu, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-16464-5 · Cited by 25
Immunity, Vascular Aging and Stroke
Louka, A. M., Sagris, D., & Ntaios, G. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220103101700 · Cited by 26
Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention
Akam, E. Y., Nuako, A. A., Daniel, A. K., & Stanford, F. C. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01451-6 · Cited by 26
Screening for coronary artery disease in asymptomatic individuals: Why and how?
Degrell, P., Sorbets, E., Feldman, L. J., Steg, P. G., & Ducrocq, G. (2015) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2015.10.001 · Cited by 26
Buland, J. R., Wasserloos, K., Tyurin, V. A., Tyurina, Y. Y., Amoscato, A. A., Mallampalli, R. K., Chen, B. B., Zhao, J., Zhao, Y., Ofori-Acquah, S. F., et al. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00038.2016 · Cited by 25
Long-term effects on lipid metabolism of weight reduction on lactovegetarian and mixed diet.
Marniemi, J., Seppänen, A., & Hakala, P. (1990) · PubMed · Cited by 25
Li, Y., Wang, Y., Chen, Y., Wang, Y., Zhang, S., Liu, P., Chen, Z., Song, P., Luo, L., Luo, Y., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01611 · Cited by 24
Inflammation, plaque progression and vulnerability: evidence from intravascular ultrasound imaging.
Kataoka, Y., Puri, R., & Nicholls, S. J. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2223-3652.2015.05.06 · Cited by 24
Daminelli, E. N., Martinelli, A. E. M., Bulgarelli, A., Freitas, F. R., & Maranhão, R. C. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6675-0 · Cited by 24
Sun, S., Zhang, M., Yang, Q., Shen, Z., Chen, J., Yu, B., Wang, H., Qu, J., Pang, D., Ren, W., et al. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201601112 · Cited by 24
Metabolic regulation of immunological aging
Kim, H., & Dixit, V. D. (2025) · Nature Aging · doi:10.1038/s43587-025-00921-2 · Cited by 30
Roggero, A., Toyama, M. H., & Sousa, S. F. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00482 · Cited by 27
Ge, P.-C., Chen, Z.-H., Pan, R.-Y., Ding, X., Liu, J.-Y., Jia, Q., Liu, Z., He, S.-Z., An, F., Li, L., et al. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000453153 · Cited by 23
Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Patients With Parkinson’s Disease
Wu, Z., Wu, S., Liang, T., & Wang, L. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.633022 · Cited by 23
Woolford, A. J. ‐., Pero, J. E., Aravapalli, S., Berdini, V., Coyle, J. E., Day, P. J., Dodson, A. M., Grondin, P., Holding, F. P., Lee, L. Y. W., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00212 · Cited by 23
Subsequent Event Risk in Individuals With Established Coronary Heart Disease
Patel, R. S., Tragante, V., Schmidt, A. F., McCubrey, R. O., Holmes, M. V., Howe, L. J., Direk, K., Åkerblom, A., Leander, K., Virani, S. S., et al. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002470 · Cited by 23
Colchicine for the treatment of coronary artery disease
Aimo, A., Pascual-Figal, D. A., Barison, A., Cediel, G., Vicente, Á. H., Saccaro, L. F., Emdin, M., & Bayés‐Genís, A. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.10.007 · Cited by 24
Fenning, R. S., Burgert, M. E., Hamamdzic, D., Peyster, E. G., Mohler, E. R., Kangovi, S., Jucker, B. M., Lenhard, S. C., Macphee, C. H., & Wilensky, R. L. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001477 · Cited by 22
Poulsen, C. B., Al‐Mashhadi, A. L., von Wachenfeldt, K. A., Bentzon, J. F., Nielsen, L. B., Al-Mashhadi, R. H., Thygesen, J., Tolbod, L. P., Larsen, J. R., Frøkiær, J., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.03.222 · Cited by 22
Tufaro, V., Serruys, P. W. J. C., Räber, L., Bennett, M. R., Torii, R., Gu, S. Z., Onuma, Y., Mathur, A., Baumbach, A., & Bourantas, C. V. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac051 · Cited by 22
Novel Biomarkers for Cardiovascular Risk Assessment: Current Status and Future Directions
MacNamara, J. P., Eapen, D. J., Quyyumi, A. A., & Sperling, L. S. (2015) · Future Cardiology · doi:10.2217/fca.15.39 · Cited by 23
Centurión, O. A. (2016) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2016.01.005 · Cited by 22
Wang, C., Fang, X., Yang, H., Liu, Y., Zhang, Z., Gu, X., Wu, X., Tang, Z., Guan, S., Liu, H., et al. (2017) · Angiology · doi:10.1177/0003319717704554 · Cited by 22
Li, J., Wang, H., Tian, J., Chen, B., & Du, F. (2018) · Medicine · doi:10.1097/md.0000000000011517 · Cited by 22
Sweeney, T. E., Quispe, R., Das, T. M., Juraschek, S. P., Martin, S. S., & Michos, E. D. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1930531 · Cited by 24
Wudexi, I., Shokri, E., Abo-Aly, M. A., Shindo, K., & Abdel‐Latif, A. (2021) · Mediators of Inflammation · doi:10.1155/2021/5160728 · Cited by 21
Anti-Monomeric C-Reactive Protein Antibody Ameliorates Arthritis and Nephritis in Mice
Fujita, C., Sakurai, Y., Yasuda, Y., Takada, Y., Huang, C.-L., & Fujita, M. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100349 · Cited by 21
Oxidized phospholipids and lipoprotein(a): An update
Koutsogianni, A. D., Liberopoulos, E. N., Tellis, K., & Tselepis, A. D. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13710 · Cited by 21
Inflammation as a Mechanism and Therapeutic Target in Peripheral Artery Disease
Chan, N., Xu, K., de Vries, T. A. C., Eikelboom, J. W., & Hirsh, J. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.01.026 · Cited by 22
Xu, J., Ma, H., Shi, L., Zhou, H. R., Cheng, Y., Tong, J., Meng, B., Xu, X., He, K., Ding, S., et al. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319905 · Cited by 22
Han, X., Wang, T., Zhang, J., Liu, X., Li, Z., Wang, G., Song, Q., Pang, D., Ouyang, H., & Tang, X. (2015) · Biology Open · doi:10.1242/bio.201410900 · Cited by 22
Lipoprotein-Associated Phospholipase A 2 and Incident Peripheral Arterial Disease in Older Adults
Garg, P. K., Arnold, A. M., Stukovsky, K. H., Koro, C. E., Jenny, N. S., Mukamal, K. J., Criqui, M. H., Furberg, C. D., Newman, A. B., & Cushman, M. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306647 · Cited by 21
New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk
Graham, I. M., Shear, C. L., de Graeff, P., Boulton, C., Catapano, A. L., Stough, W. G., Carlsson, S. C., Backer, G. D., Emmerich, J., Greenfeder, S. A., et al. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvx031 · Cited by 21
Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans
Ferrannini, E., Manca, M. L., Ferrannini, G., Andreotti, F., Andreini, D., Latini, R., Magnoni, M., Williams, S. A., Maseri, A., & Maggioni, A. P. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.790289 · Cited by 20
Gleissner, C. A. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.013 · Cited by 21
Woolford, A. J. ‐., Day, P. J., Bénéton, V., Berdini, V., Coyle, J. E., Dudit, Y., Grondin, P., Huet, P., Lee, L. Y. W., Manas, E. S., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01427 · Cited by 20
Targeting Inflammation in the Prevention and Treatment of Type 2 Diabetes
Verma, S., Mathew, V., & Farkouh, M. E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.480 · Cited by 21
Risk markers of incident atrial fibrillation in patients with coronary heart disease
Tomasdottir, M., Held, C., Hadziosmanovic, N., Westerbergh, J., Lindbäck, J., Aylward, P. E., Budaj, A., Cannon, C. P., Engdahl, J., Granger, C. B., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2020.12.016 · Cited by 19
New Insights into Pathophysiology and New Risk Factors for ACS
Nardin, M., Verdoia, M., Laera, N., Cao, D., & Luca, G. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082883 · Cited by 21
New and Emerging Biomarkers in Cardiovascular Disease
Cahill, L. E., Bertoia, M. L., Aroner, S. A., Mukamal, K. J., & Jensen, M. K. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0661-y · Cited by 20
Liu, Q., Chen, X., Chen, W., Yuan, X., Su, H., Shen, J., & Xu, Y. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00282 · Cited by 19
Arsenault, B. J., Perrot, N., & Puri, R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1110 · Cited by 21
Li, S., Li, J., & Xu, H. (2018) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-018-2995-1 · Cited by 19
Mitsis, A., Kyriakou, M., Sokratous, S., Karmioti, G., Drakomathioulakis, M., Myrianthefs, M. M., Ziakas, A., Tzikas, S., & Kassimis, G. (2024) · Biomedicines · doi:10.3390/biomedicines12030701 · Cited by 18
Garg, P. K., Norby, F. L., Polfus, L. M., Boerwinkle, E., Gibbs, R. A., Grove, M. L., Folsom, A. R., Garimella, P. S., Matsushita, K., Hoogeveen, R. C., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.11.007 · Cited by 18
Lipoprotein-associated phospholipase A2 predicts cardiovascular events in dialyzed patients
Mauri, A. D., Vidali, M., Chiarinotti, D., Bellomo, G., & Rolla, R. (2018) · Journal of Nephrology · doi:10.1007/s40620-018-0521-3 · Cited by 18
Looking back and thinking forwards — 15 years of cardiology and cardiovascular research
Kalman, J. M., Lavandero, S., Mahfoud, F., Nahrendorf, M., Yacoub, M. H., & Zhao, D. H. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0261-7 · Cited by 17
Perrot, N., Thériault, S., Rigade, S., Chen, H. Y., Dina, C., Martinsson, A., Boekholdt, S. M., Capoulade, R., Tourneau, T. L., Messika–Zeitoun, D., et al. (2020) · Heart · doi:10.1136/heartjnl-2020-316722 · Cited by 18
Diverse Functions of Plasma PAF-AH in Tumorigenesis
Stafforini, D. M. (2015) · The Enzymes · doi:10.1016/bs.enz.2015.09.005 · Cited by 18
How Might Bromodomain and Extra-Terminal (BET) Inhibitors Operate in Cardiovascular Disease?
Schooling, C. M., & Zhao, J. V. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-00315-3 · Cited by 17
Anti-inflammatory Treatment and Cardiovascular Outcomes: Results of Clinical Trials
Lorenzatti, A. J. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.51 · Cited by 17
Siddiqui, M. K., Smith, G. C., Jean, P. S., Dawed, A. Y., Bell, S., Soto‐Pedre, E., Kennedy, G., Carr, F., Wallentin, L. C., White, H. D., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05574-5 · Cited by 17
Pokharel, Y., Sun, W., Polfus, L. M., Folsom, A. R., HEISS, G. M., Sharrett, A. R., Boerwinkle, E., Ballantyne, C. M., & Hoogeveen, R. C. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.033 · Cited by 17
Held, C., White, H. D., Stewart, R., Davies, R., Sampson, S. H., Chiswell, K., Silverstein, A. P., Lópes, R. D., Heldestad, U., Budaj, A., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.10.010 · Cited by 17
Association of Factor V Leiden With Subsequent Atherothrombotic Events
Mahmoodi, B. K., Tragante, V., Kleber, M. E., Holmes, M. V., Schmidt, A. F., McCubrey, R. O., Howe, L. J., Direk, K., Allayee, H., Baranova, E. V., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.045526 · Cited by 18
Mourouzis, K., Siasos, G., Oikonomou, E. K., Zaromitidou, M., Tsigkou, V., Antonopoulos, A. S., Bletsa, E., Stampouloglou, P. K., Vlasis, K. G., Vavuranakis, M., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01438-4 · Cited by 17
Vulnerable Plaques, Vulnerable Patients, and Intravascular Imaging
Stone, G. W., Mintz, G. S., & Virmani, R. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.010 · Cited by 17
Zhang, Y., Li, F., Liu, L., An, Z., Luo, H., Zhang, H., Ma, R., Zhang, R., Dai, Q., Zhang, M., et al. (2025) · Advanced Science · doi:10.1002/advs.202504990 · Cited by 19
The impact of colchicine on patients with acute and chronic coronary artery disease
Madanchi, M., Young, M., Tersalvi, G., Cioffi, G. M., Attinger‐Toller, A., Cuculi, F., Kurmann, R., & Bossard, M. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.01.004 · Cited by 17
Imaging as a surrogate marker of drug efficacy in cardiovascular disease
Tarkin, J. M., Dweck, M. R., & Rudd, J. H. F. (2018) · Heart · doi:10.1136/heartjnl-2017-311213 · Cited by 16
Olszowka, M., Held, C., Hadziosmanovic, N., Denchev, S., Manolis, A. J., Wallentin, L. C., White, H. D., Stewart, R., Hagström, E., & the STABILITY Investigators (2021) · Journal of Internal Medicine · doi:10.1111/joim.13294 · Cited by 19
Self-citationAtherosclerosis revisited from a clinical perspective: still an inflammatory disease?
Santovito, D., & Weber, C. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-10-0770 · Cited by 15
An overview of the innate and adaptive immune system in atherosclerosis
Mohammad-Rezaei, M., Arefnezhad, R., Ahmadi, R., Abdollahpour‐Alitappeh, M., Mirzaei, Y., Arjmand, M., Ferns, G. A., Bashash, D., & Bagheri, N. (2020) · IUBMB Life · doi:10.1002/iub.2425 · Cited by 16
Understanding the Adverse Effects of Ticagrelor in Practice
Granger, C. B., & Berger, P. B. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1018 · Cited by 16
Takagahara, S., Shinohara, H., Itokawa, S., Satomi, Y., Ando, A., Yamamoto, T., Suzuki, H., Fujimoto, T., Kubo, K., & Ikeda, S. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.259846 · Cited by 15
Abubakar, M., Irfan, U., Abdelkhalek, A., Javed, I., Khokhar, M. I., Shakil, F., Raza, S., Salim, S. S., Altaf, M. M., Habib, R., et al. (2024) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-024-10540-8 · Cited by 15
Chen, J., Zhang, H., Li, L., Zhang, X., Zhao, D., Wang, L., Wang, J., Yang, P. C., Sun, H., Liu, K., et al. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317898 · Cited by 14
Why do statins reduce cardiovascular disease more than other lipid modulating therapies?
Schooling, C. M., Yeung, S. L. A., & Leung, G. M. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12342 · Cited by 15
Madonna, R., Selvaggio, S., Selvaggio, G., Coronelli, M. M., & Cocco, N. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.03.205 · Cited by 15
Bokhari, S. F. H., Umais, M., Sattar, S. M. F., Mehboob, U., Iqbal, A., Amir, M., Bakht, D., Ali, K., Hasan, A. H., Javed, M. A., et al. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i7.106561 · Cited by 17
Colchicine for the Prevention of Cardiovascular Disease: Potential Global Implementation
Zhang, R. S., Weber, B., Garaygordobil, D. A., & Garshick, M. S. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02049-y · Cited by 17
Mayer, O., Seidlerová, J., Filipovský, J., Timoracká, K., Bruthans, J., Vaněk, J., Černá, L., Wohlfahrt, P., Cífková, R., & Trefil, L. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.05.010 · Cited by 14
Self‐Reported Health and Outcomes in Patients With Stable Coronary Heart Disease
Stewart, R., Hagström, E., Held, C., Wang, T. K. M., Armstrong, P. W., Aylward, P. E., Cannon, C. P., Köenig, W., Lopez-Sendon, J. L., Mohler, E. R., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006096 · Cited by 15
Otsuka, F., Zhao, X., Trout, H. H., Qiao, Y., Wasserman, B. A., Nakano, M., Macphee, C. H., Brandt, M. A., Krug‐Gourley, S., Guo, L., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.014 · Cited by 14
Yi, L., Zhang, J., Zhong, J.-R., & Zheng, Y. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2019.0141 · Cited by 14
Anti-inflammatory strategies for atherosclerotic artery disease
Agnello, F. G., & Capodanno, D. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2036717 · Cited by 14
Davidsson, P., Eketjäll, S., Eriksson, N., Walentinsson, A., Becker, R. C., Cavallin, A., Bogstedt, A., Collén, A., Held, C., James, S. K., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad039 · Cited by 14
Metadata
- Authors
- The STABILITY Investigators
- Affiliations
- University of Auckland (NZ)
- Corresponding author
- The STABILITY Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05
- Volume
- 370
- Issue
- 18
- Pages
- 1702-1711
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1572528121
- Cited by
- 579
- References
- 22
- Citations by year
- 2026: 23 · 2025: 34 · 2024: 33 · 2023: 27 · 2022: 47 · 2021: 38 · 2020: 34 · 2019: 36 · 2018: 48 · 2017: 63 · 2016: 71 · 2015: 85 · 2014: 37
- FWCI
- 85.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Funders
- Uppsala Universitet
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- darapladib, lipoprotein-associated phospholipase A2, stable coronary artery disease, cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, major coronary events, all-cause mortality, atherosclerotic plaque vulnerability, lipid-lowering therapy, unstable angina
- MeSH terms
- Aged, Benzaldehydes, Biphenyl Compounds, Coronary Artery Disease, Coronary Disease, Diethylamines, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Oximes, Pyrimidinones, Sulfides, Treatment Failure, Stroke, Kaplan-Meier Estimate, Phospholipase A2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
